BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 17540209)

  • 1. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study.
    Yamada T; Node K; Mine T; Morita T; Kioka H; Tsukamoto Y; Tamaki S; Masuda M; Okuda K; Fukunami M
    Am Heart J; 2007 Jun; 153(6):1055.e1-8. PubMed ID: 17540209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure.
    Vrtovec B; Okrajsek R; Golicnik A; Ferjan M; Starc V; Schlegel TT; Radovancevic B
    J Card Fail; 2008 Mar; 14(2):140-4. PubMed ID: 18325461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy.
    Bielecka-Dabrowa A; Goch JH; Mikhailidis DP; Rysz J; Maciejewski M; Banach M
    Med Sci Monit; 2009 Dec; 15(12):MS12-23. PubMed ID: 19946241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide.
    Abulhul E; McDonald K; Martos R; Phelan D; Spiers JP; Hennessy M; Baugh J; Watson C; O'Loughlin C; Ledwidge M
    Clin Ther; 2012 Jan; 34(1):91-100. PubMed ID: 22154198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
    Bauersachs J; Störk S; Kung M; Waller C; Fidler F; Hoyer C; Frantz S; Weidemann F; Ertl G; Angermann CE
    Eur J Clin Invest; 2007 Nov; 37(11):852-9. PubMed ID: 17973781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma brain natriuretic peptide predicts short-term clinical outcome in heart failure patients with restrictive filling pattern.
    Feola M; Aspromonte N; Milani L; Bobbio M; Bardellotto S; Barro S; Giovinazzo P; Noventa F; Valle R
    J Card Fail; 2008 Jun; 14(5):420-5. PubMed ID: 18514935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity.
    Castro PF; Miranda R; Verdejo HE; Greig D; Gabrielli LA; Alcaino H; Chiong M; Bustos C; Garcia L; Mellado R; Vukasovic JL; Godoy I; Lavandero S
    J Heart Lung Transplant; 2008 Apr; 27(4):435-41. PubMed ID: 18374881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure.
    Sasaki T; Kubo T; Komamura K; Nishikimi T
    J Cardiol; 1999 Jun; 33(6):317-25. PubMed ID: 10396705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta-Blocker Evaluation of Survival Study (BEST).
    Frantz RP; Lowes BD; Grayburn PA; White M; Krause-Steinrauf H; Krishnan V; Uyeda L; Burnett JC;
    J Card Fail; 2007 Aug; 13(6):437-44. PubMed ID: 17675057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of phosphocreatine on plasma brain natriuretic peptide level in elderly patients with chronic congestive heart failure].
    Du XH; Liang FY; Zhao XW
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jan; 29(1):154-5, 159. PubMed ID: 19218138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
    Mozaffarian D; Minami E; Letterer RA; Lawler RL; McDonald GB; Levy WC
    Am J Cardiol; 2005 Dec; 96(12):1699-704. PubMed ID: 16360360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility, safety, and mid-term efficacy of cardiac resynchronization therapy in patients with severe heart failure and ventricular conduction delay: Chulalongkorn experience.
    Sunsaneewitayakul B; Sitthisook S; Sangwatanaroj S; Prechawat S; Songmuang SB
    J Med Assoc Thai; 2007 Jul; 90(7):1458-66. PubMed ID: 17710992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
    Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction.
    Teshima Y; Yufu K; Akioka H; Iwao T; Anan F; Nakagawa M; Yonemochi H; Takahashi N; Hara M; Saikawa T
    J Cardiol; 2009 Feb; 53(1):58-64. PubMed ID: 19167639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of elderly patients with congestive heart failure--design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF).
    Brunner-La Rocca HP; Buser PT; Schindler R; Bernheim A; Rickenbacher P; Pfisterer M;
    Am Heart J; 2006 May; 151(5):949-55. PubMed ID: 16644310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.
    Krum H; Ashton E; Reid C; Kalff V; Rogers J; Amarena J; Singh B; Tonkin A
    J Card Fail; 2007 Feb; 13(1):1-7. PubMed ID: 17338996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The clinical value of B-type natriuretic peptide in the diagnosis of left heart failure].
    Zhao XY; Yang YJ; Zhang J; Dang AM; Ni XH; Huang J; Kang S; Ma WH; Zhao DY
    Zhonghua Yi Xue Za Zhi; 2006 May; 86(17):1165-9. PubMed ID: 16796855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia.
    Palazzuoli A; Silverberg DS; Calabrò A; Spinelli T; Quatrini I; Campagna MS; Franci B; Nuti R
    J Cardiovasc Pharmacol; 2009 Jun; 53(6):462-7. PubMed ID: 19455052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.